^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SPH5030

    i
    Other names: SPH5030, I025-A, SPH-5030
    Associations

    News

    Trials
    Company:
    Shanghai Pharma
    Drug class:
    HER2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    10ms
    SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    SPH5030
    1year
    SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | N=114 --> 150
    Enrollment change • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    SPH5030
    over1year
    Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy. (PubMed, Eur J Med Chem)
    Currently, widely used clinical HER2 tyrosine kinase inhibitors (TKIs), such as lapatinib and neratinib, have several drawbacks, including susceptibility to drug resistance caused by HER2 mutations and adverse effects from insufficient HER2 selectivity...Typically, SPH5030 has advanced to phase I clinical trials for its strong suppression of four HER2 mutations. This review discusses the latest research progress in HER2 TKIs, with a focus on the structural optimization process and structure-activity relationship analysis. In particular, this study highlights promising design strategies to address these challenges, providing insightful information and inspiration for future development in this field.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    lapatinib • Nerlynx (neratinib) • SPH5030
    over1year
    SPH5030-201: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. (clinicaltrials.gov)
    P2, N=60, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SPH5030
    over1year
    SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors (clinicaltrials.gov)
    P1, N=114, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    SPH5030
    over1year
    A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Shanghai Pharmaceuticals Holding Co., Ltd
    New P2 trial
    |
    SPH5030
    over1year
    A Food Effect Study of SPH5030 Tablets. (clinicaltrials.gov)
    P1, N=16, Completed, Shanghai Pharmaceuticals Holding Co., Ltd
    New P1 trial
    |
    SPH5030
    almost4years
    SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors (clinicaltrials.gov)
    P1, N=105, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    SPH5030